EDITAS MEDICINE, INC. Deferred Revenue Recognized
EDITAS MEDICINE, INC. (EDIT) reported Deferred Revenue Recognized of $15.92 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-03-09
- EDITAS MEDICINE, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $0.00.
- EDITAS MEDICINE, INC. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $2.00M.
- EDITAS MEDICINE, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-09-30 was $0.00.
- EDITAS MEDICINE, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-06-30 was $0.00.
- EDITAS MEDICINE, INC. contract with customer, liability, revenue recognized for fiscal 2025 was $15.92M, a 88.07% increase from fiscal 2024.
- EDITAS MEDICINE, INC. contract with customer, liability, revenue recognized for fiscal 2024 was $8.46M.
- EDITAS MEDICINE, INC. contract with customer, liability, revenue recognized for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- EDITAS MEDICINE, INC. contract with customer, liability, revenue recognized for fiscal 2022 was $11.48M, a 49.43% decline from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2025-12-31 | $15.92M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $6.22M 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $2.00M 10-Q · filed 2025-08-12 | $6.22M 10-Q · filed 2025-08-12 | ||
| 2024-12-31 | $8.46M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-05 | |||
| 2022-12-31 | $11.48M 10-K · filed 2023-02-22 | |||
| 2022-09-30 | $11.48M 10-Q · filed 2022-11-02 | |||
| 2022-06-30 | $5.67M 10-Q · filed 2022-08-03 | $11.48M 10-Q · filed 2022-08-03 | ||
| 2022-03-31 | $5.67M 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $11.33M 10-K · filed 2022-02-24 | $22.71M 10-K · filed 2022-02-24 | ||
| 2021-09-30 | $5.67M 10-Q · filed 2021-11-09 | $11.37M 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | $5.71M 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $5.71M 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $5.77M 10-K · filed 2021-02-26 | $92.30M 10-K · filed 2021-02-26 | ||
| 2020-09-30 | $78.65M 10-Q · filed 2020-11-06 | $86.53M 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | $3.07M 10-Q · filed 2020-08-07 | $7.88M 10-Q · filed 2020-08-07 | ||
| 2020-03-31 | $4.82M 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | $4.71M 10-K · filed 2020-02-26 | $11.45M 10-K · filed 2020-02-26 | ||
| 2019-09-30 | $2.35M 10-Q · filed 2019-11-12 | $6.73M 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $2.32M 10-Q · filed 2019-08-07 | $4.38M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $2.06M 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $1.42M 10-K · filed 2019-03-01 | $5.87M 10-K · filed 2019-03-01 | ||
| 2018-09-30 | $687.00K 10-Q · filed 2018-11-08 | $4.46M 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | $875.00K 10-Q · filed 2018-08-07 | $3.77M 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | $2.90M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |